Fractyl Health Stock (NASDAQ:GUTS)

Fractyl Health, Inc. is a biopharmaceutical firm dedicated to advancing treatments for type 2 diabetes (T2D) and obesity. Among its offerings is the Revita DMR System (Revita), an outpatient procedure engineered to provide lasting modification of duodenal dysfunction. This condition often arises from diets high in fat and sugar, playing a role in the onset of T2D and obesity in individuals. Fractyl Health is also pioneering Rejuva, an innovative gene therapy platform utilizing a viral delivery system directly to the pancreas. Rejuva's objective is to achieve long-term remission from T2D and obesity by fundamentally altering metabolic hormone function within patients' pancreatic islet cells. Incorporated in 2010, the company, formerly known as Fractyl Laboratories Inc., officially became Fractyl Health, Inc. on June 9, 2021. Its operations are headquartered in Lexington, Massachusetts.